



Lucitanib hydrochloride

is a novel dual inhibitor targeting human vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs) with antiangiogenic activity

Lucitanib, a new potent and orally available agent, is a selective dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR), showing antiangiogenic and antitumoral activities in vivo in rodent models. In a phase I/IIa clinical trial in patients with FGF-aberrant breast cancer, lucitanib showed an outstanding objective response rate of 50%, progression-free survival of 40 weeks, median time to response of 8 weeks and duration of response of 49 weeks.

Contribution : Abdallah HAMZE March 2016